edmund ho
Singapore (USA)
Role(s):
Other
EMINENCE MEDICAL EQUIPMENT PTE. LTD.
Find More Startups
Startup
Location:
Singapore
Industry:
Technology/Web
Year Founded:
2002
Number Employees:
1-10 people
Business Stage:
Growth (not profitable)
Entity Type:
Incorporated Outside United States
Description:
Let me give you a brief overview. Our company with Headquarters in Singapore is developing non-invasive, cost-effective and user-friendly medical devices based on the Vectorcardiography(VCG) rather than ECG for front line accurate diagnosis of heart diseases.
We are developing a range of products for professional and home use. With the devices incorporating superior VCG technology and other latest cardiac diagnostic technologies, we can reduce the incidences and deaths due to heart diseases by 20-30% and bring down healthcare costs substantially. Having our device is like having a cardiologist at your standby 24/7 without all the costs and hassle! The device is further supported by telemedicine system as part of a patient centric ecosystem. This early detection is going to bring about a great revolution in the diagnosis and treatment of heart diseases.
With this big potential, we are doing a limited period Pre-IPO funding to speed up our access to markets. In fact, Eminence is planning to be listed in Frankfort Stock Exchange in 2015! (i.e. about 3 years from now).
Currently, we are raising a Pre-IPO round of funding of up to USD 5 million. The minimum amount of investment we can work with is USD$100k per investor. Currently, we have a paid-up capital of SGD2,486,002-. The pre money valuation of Eminence is USD 7.5 million for this round of fund raising.
By 2015, based on the forecast results of Eminence in 2014 (revenue ~ USD 80 million and net profit ~ USD 12 million) and assuming a price to earnings ratio of 10x after IPO, Eminence will have a market capitalisation of ~ USD 100 million. As a result of which, investors of this round will get a return of over 10 times on capital invested over 3 years or an Internal Rate of Return (IRR) of > 100% p.a.
We have come far from a startup. The prototypes for our Cardiohealth devices are ready and we are pending approval from regulatory bodies. Our devices are non-invasive, comprehensive, accurate, user friendly and more affordable than what the market offers. There is simply no comparison in the market for our product in terms of accuracy and sophistication. Prior to sales of our devices, we have already lined up a great management team worldwide and regional distributors will be given exclusive licenses to market our great products.
This is an interesting opportunity in life sciences not to be missed. We envision the future where smart, simple, fast, robust, portable and cost-effective clinical diagnosis systems is made available in the convenience of everyone’s home!